Publications

NAR genomics and bioinformatics

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

01-03-2026

Therapeutic drug monitoring

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

13-02-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

27-10-2025

European urology oncology

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

30-09-2025

European urology oncology

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

Communications biology

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

11-07-2025

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with ²²³Ra Therapy in Daily Practice.

01-07-2025

Clinical genitourinary cancer

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

01-06-2025

European urology oncology

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

13-05-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

10-05-2025

British journal of cancer

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

01-04-2025

Genome medicine

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

20-03-2025

Cancer discovery

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

03-03-2025

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

European urology oncology

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.

01-10-2024

The Journal of clinical investigation

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

13-08-2024

Clinical genitourinary cancer

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

01-04-2024

NPJ systems biology and applications

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

21-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Cancers

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

10-01-2024

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.

31-12-2023

Pharmaceutical research

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

01-12-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Cancers

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.

29-05-2023

Prostate cancer and prostatic diseases

Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry.

01-03-2023

European urology open science

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

01-03-2023

Urologic oncology

Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.

01-02-2023

European urology open science

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl).

01-02-2023

European urology oncology

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.

01-02-2023

Clinica chimica acta; international journal of clinical chemistry

Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.

15-01-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020

Key